Ghinwa Dumyati
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Cross Infection | 7 | 2006 | 46 |
Why?
|
Staphylococcal Infections | 7 | 2006 | 63 |
Why?
|
Population Surveillance | 4 | 2007 | 70 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 6 | 2009 | 5 |
Why?
|
Bacteremia | 2 | 2010 | 25 |
Why?
|
Catheter-Related Infections | 1 | 2011 | 6 |
Why?
|
Levamisole | 1 | 2010 | 6 |
Why?
|
Catheterization, Central Venous | 1 | 2011 | 46 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2010 | 5 |
Why?
|
Drug Contamination | 1 | 2010 | 14 |
Why?
|
Cheek | 1 | 2010 | 20 |
Why?
|
Ear, External | 1 | 2010 | 23 |
Why?
|
Cocaine-Related Disorders | 1 | 2010 | 22 |
Why?
|
Adjuvants, Immunologic | 1 | 2010 | 73 |
Why?
|
Community-Acquired Infections | 6 | 2006 | 17 |
Why?
|
Clostridium difficile | 2 | 2009 | 9 |
Why?
|
Enterocolitis, Pseudomembranous | 2 | 2009 | 17 |
Why?
|
Influenza, Human | 2 | 1992 | 94 |
Why?
|
Antiviral Agents | 1 | 2002 | 91 |
Why?
|
Antibiotic Prophylaxis | 2 | 2008 | 22 |
Why?
|
Surgical Wound Infection | 2 | 2008 | 41 |
Why?
|
Anti-Bacterial Agents | 3 | 2009 | 195 |
Why?
|
Methicillin Resistance | 2 | 2006 | 9 |
Why?
|
Young Adult | 5 | 2009 | 380 |
Why?
|
Staphylococcus aureus | 2 | 2006 | 48 |
Why?
|
Virulence Factors | 2 | 2009 | 24 |
Why?
|
Catheters | 1 | 2011 | 5 |
Why?
|
Humans | 17 | 1992 | 1856 |
Why?
|
Vancomycin Resistance | 1 | 2011 | 3 |
Why?
|
Necrosis | 1 | 2010 | 82 |
Why?
|
Staphylococcal Vaccines | 1 | 2009 | 4 |
Why?
|
Middle Aged | 8 | 1992 | 1161 |
Why?
|
Neutropenia | 1 | 2010 | 42 |
Why?
|
Staphylococcal Skin Infections | 1 | 2009 | 3 |
Why?
|
Feces | 1 | 2009 | 43 |
Why?
|
United States | 7 | 2006 | 604 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 4 | 2006 | 17 |
Why?
|
Sequence Analysis, DNA | 1 | 2009 | 110 |
Why?
|
Quality Indicators, Health Care | 1 | 2008 | 34 |
Why?
|
Hospitals | 1 | 2008 | 46 |
Why?
|
Reproducibility of Results | 1 | 2011 | 391 |
Why?
|
Aged | 8 | 1992 | 988 |
Why?
|
Adult | 6 | 2009 | 1317 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 279 |
Why?
|
Prospective Studies | 1 | 2011 | 545 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2009 | 145 |
Why?
|
Bacterial Proteins | 1 | 2009 | 99 |
Why?
|
Attitude of Health Personnel | 1 | 2009 | 165 |
Why?
|
Adolescent | 5 | 2009 | 891 |
Why?
|
Child, Preschool | 4 | 2009 | 554 |
Why?
|
Female | 6 | 1992 | 1643 |
Why?
|
Rimantadine | 1 | 2002 | 7 |
Why?
|
Zanamivir | 1 | 2002 | 9 |
Why?
|
Oseltamivir | 1 | 2002 | 8 |
Why?
|
Pyrans | 1 | 2002 | 11 |
Why?
|
Amantadine | 1 | 2002 | 19 |
Why?
|
Guanidines | 1 | 2002 | 26 |
Why?
|
Acetamides | 1 | 2002 | 20 |
Why?
|
Sialic Acids | 1 | 2002 | 17 |
Why?
|
Drug Resistance, Viral | 1 | 2002 | 17 |
Why?
|
Child | 4 | 2009 | 749 |
Why?
|
Aged, 80 and over | 4 | 1992 | 599 |
Why?
|
Infant | 3 | 2010 | 464 |
Why?
|
Influenza Vaccines | 2 | 1992 | 70 |
Why?
|
Infection Control | 2 | 2009 | 20 |
Why?
|
DNA Fingerprinting | 2 | 2009 | 7 |
Why?
|
Practice Guidelines as Topic | 1 | 2002 | 174 |
Why?
|
Microbial Sensitivity Tests | 2 | 2009 | 71 |
Why?
|
Risk Factors | 3 | 2007 | 555 |
Why?
|
Incidence | 2 | 2010 | 336 |
Why?
|
Genotype | 2 | 2009 | 175 |
Why?
|
Antibodies, Viral | 2 | 1992 | 104 |
Why?
|
Influenza B virus | 1 | 1994 | 16 |
Why?
|
Male | 5 | 1992 | 1553 |
Why?
|
Disease Outbreaks | 2 | 1992 | 61 |
Why?
|
Metronidazole | 1 | 2011 | 11 |
Why?
|
Fluoroquinolones | 1 | 2011 | 14 |
Why?
|
Health Facilities | 1 | 2010 | 8 |
Why?
|
England | 1 | 2010 | 20 |
Why?
|
Influenza A virus | 1 | 1992 | 63 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 123 |
Why?
|
Bacterial Typing Techniques | 1 | 2009 | 15 |
Why?
|
Enterotoxins | 1 | 2009 | 15 |
Why?
|
Cephalexin | 1 | 2009 | 8 |
Why?
|
Trimethoprim-Sulfamethoxazole Combination | 1 | 2009 | 12 |
Why?
|
Outpatients | 1 | 2009 | 29 |
Why?
|
Multivariate Analysis | 1 | 2011 | 225 |
Why?
|
ADP Ribose Transferases | 1 | 2009 | 9 |
Why?
|
Joints | 1 | 2009 | 19 |
Why?
|
Cluster Analysis | 1 | 2009 | 66 |
Why?
|
Blood | 1 | 2009 | 67 |
Why?
|
Immunization Programs | 1 | 2009 | 24 |
Why?
|
Bacterial Toxins | 1 | 2009 | 24 |
Why?
|
Feedback | 1 | 2008 | 54 |
Why?
|
Recurrence | 1 | 2011 | 261 |
Why?
|
Cost of Illness | 1 | 2009 | 54 |
Why?
|
DNA, Bacterial | 1 | 2009 | 67 |
Why?
|
Genetic Variation | 1 | 2009 | 91 |
Why?
|
Cooperative Behavior | 1 | 2008 | 70 |
Why?
|
Hospitalization | 1 | 2011 | 169 |
Why?
|
Aging | 1 | 1994 | 275 |
Why?
|
Logistic Models | 1 | 2009 | 251 |
Why?
|
Infant, Newborn | 1 | 2011 | 389 |
Why?
|
Cohort Studies | 1 | 2009 | 332 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 427 |
Why?
|
Bone and Bones | 1 | 2009 | 99 |
Why?
|
Retrospective Studies | 1 | 2011 | 653 |
Why?
|
New York | 1 | 2009 | 422 |
Why?
|
Base Sequence | 1 | 2009 | 371 |
Why?
|
Questionnaires | 1 | 2009 | 360 |
Why?
|
Vaccines, Attenuated | 2 | 1992 | 22 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 404 |
Why?
|
Treatment Outcome | 1 | 2011 | 661 |
Why?
|
Time Factors | 1 | 2009 | 896 |
Why?
|
Double-Blind Method | 2 | 1992 | 274 |
Why?
|
Cold Temperature | 1 | 1994 | 59 |
Why?
|
Vaccines, Inactivated | 1 | 1992 | 15 |
Why?
|
Administration, Intranasal | 1 | 1992 | 25 |
Why?
|
Injections, Intramuscular | 1 | 1992 | 43 |
Why?
|
Homes for the Aged | 1 | 1992 | 25 |
Why?
|
Vaccination | 1 | 1994 | 92 |
Why?
|
Chronic Disease | 1 | 1994 | 267 |
Why?
|
Nursing Homes | 1 | 1992 | 55 |
Why?
|
